AMERGE

LOE Approaching

naratriptan hydrochloride

GSK
NDAORALTABLET
Approved
Feb 1998
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Clinical Trials
2

Clinical Trials (2)

NCT01332383N/ACompleted

Special Drug Use Investigation for AMERGE® Tablet (Long-term)

Started May 2009
300 enrolled
Migraine Disorders
NCT01376193N/ACompleted

Drug Use Investigation for AMERGE (Naratriptan Hydrochloride) Tablet

Started Apr 2009
500 enrolled
Migraine Disorders
Company
GSK
GSK
LONDON, United Kingdom
698 open jobs
External Resources
FDA Drugs@FDA
FDA approval history
RxNorm
Drug nomenclature & identifiers